NSAIDs Vs. COX-2s: Study Prompts Labeling Review By FDA On Merck’s Vioxx
This article was originally published in The Tan Sheet
Executive Summary
OTC NSAID manufacturers may have been handed a significant marketing opportunity against COX-2s in the form of results from a retrospective study indicating the Rx pain relievers carry a higher risk of a serious cardiac event compared to their nonprescription counterparts
You may also be interested in...
Pfizer’s COX-2 Scripts Take More Hits From Kaiser
A decision by Kaiser Permanente physicians in California to stop prescribing Bextra demonstrates the challenges Pfizer must overcome as it seeks to reassure the public about the cardiovascular safety of COX-2 inhibitors
Pfizer’s COX-2 Scripts Take More Hits From Kaiser
A decision by Kaiser Permanente physicians in California to stop prescribing Bextra demonstrates the challenges Pfizer must overcome as it seeks to reassure the public about the cardiovascular safety of COX-2 inhibitors
Pfizer’s COX-2 Scripts Take More Hits From Kaiser
A decision by Kaiser Permanente physicians in California to stop prescribing Bextra demonstrates the challenges Pfizer must overcome as it seeks to reassure the public about the cardiovascular safety of COX-2 inhibitors